Loss of expression of the SWI/SNF complex is a frequent event in undifferentiated/dedifferentiated urothelial carcinoma of the urinary tract
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články
PubMed
27339451
DOI
10.1007/s00428-016-1977-y
PII: 10.1007/s00428-016-1977-y
Knihovny.cz E-zdroje
- Klíčová slova
- ARID1A, Renal pelvis, Rhabdoid carcinoma, SMARCA2, SMARCB1, SWI/SNF, Undifferentiated carcinoma, Urinary bladder, Urothelial carcinoma,
- MeSH
- DNA vazebné proteiny MeSH
- DNA-helikasy metabolismus MeSH
- dospělí MeSH
- gen SMARCB1 metabolismus MeSH
- imunohistochemie metody MeSH
- jaderné proteiny metabolismus MeSH
- karcinom z přechodných buněk metabolismus patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- močové ústrojí metabolismus patologie MeSH
- rhabdoidní nádor diagnóza metabolismus patologie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- transkripční faktory metabolismus MeSH
- urologické nádory diagnóza metabolismus patologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- ARID1A protein, human MeSH Prohlížeč
- DNA vazebné proteiny MeSH
- DNA-helikasy MeSH
- gen SMARCB1 MeSH
- jaderné proteiny MeSH
- SMARCA2 protein, human MeSH Prohlížeč
- SMARCA4 protein, human MeSH Prohlížeč
- SMARCB1 protein, human MeSH Prohlížeč
- SMARCC1 protein, human MeSH Prohlížeč
- transkripční faktory MeSH
Loss of the SWI/SNF chromatin remodeling complex has been recently implicated in the pathogenesis of dedifferentiated carcinomas from different organs, but its possible role in undifferentiated urothelial carcinoma (UC) has not been studied to date. In this study, we analyzed by immunohistochemistry 14 undifferentiated UCs (11 from bladder and 3 from renal pelvis) with a nondescript anaplastic or rhabdoid morphology, using commercially available antibodies against the SWI/SNF components SMARCB1 (INI1), SMARCA2, SMARCA4, SMARCC1, SMARCC2, and ARID1A. Patients were eight females and six males aged 40 to 84 years (median, 65). All tumors were muscle-invasive (9 were T3-4). A conventional UC component was seen in eight cases and varied from in situ to papillary. The undifferentiated component comprised 60-100 % of the tumors. Histologically, most tumors showed diffuse dyscohesive or pseudoalveolar growth of variably sized cells with frequent rhabdoid features. Transition from conventional to undifferentiated UC was abrupt, except in one case. The undifferentiated component almost always expressed pan-cytokeratin AE1/AE3 (13/14) and variably vimentin (8/14) and GATA3 (9/14). Complete loss of at least one SWI/SNF subunit limited to the undifferentiated component was detected in 10/14 cases (71 %). SMARCA2 was most frequently lost (six) followed by ARID1A (four), SMARCB1/INI1 (two), SMARCA4 (one), and SMARCC1 (one). This is the first study exploring SWI/SNF expression in undifferentiated UC of the urinary tract. Our results are in line with recent studies reporting involvement of the SWI/SNF complex in the dedifferentiation process of a variety of epithelial neoplasms in different organs, including the urinary tract, and association with aggressive clinical course.
Department of Pathology Champalimaud Clinical Center Lisbon Portugal
Department of Urology and Pediatric Urology Saarland University Homburg Saar Germany
Department of Urology University Hospital of Erlangen Erlangen Germany
Indiana University School of Medicine Indianapolis IN 46202 USA
Sikl's Department of Pathology Charles University Medical Faculty Hospital Pilsen Czech Republic
Zobrazit více v PubMed
Histopathology. 2015 Jul;67(1):121-9 PubMed
Clin Cancer Res. 2016 May 15;22(10 ):2396-404 PubMed
Am J Surg Pathol. 1992 May;16(5):515-21 PubMed
Hum Pathol. 2014 Nov;45(11):2233-9 PubMed
Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):2905-8 PubMed
Can J Urol. 2015 Jun;22(3):7783-7 PubMed
Urology. 2015 Mar;85(3):664-6 PubMed
J Cancer Res Ther. 2011 Oct-Dec;7(4):486-8 PubMed
Cytopathology. 2015 Feb;26(1):54-6 PubMed
Am J Surg Pathol. 2014 Jul;38(7):910-20 PubMed
Mol Cell Biol. 2014 Mar;34(6):1136-44 PubMed
Mod Pathol. 2015 Feb;28(2):248-60 PubMed
Mod Pathol. 2008 Jun;21(6):647-52 PubMed
Pathology. 2010 Jun;42(4):364-8 PubMed
Cancer Discov. 2015 Jul;5(7):752-67 PubMed
Ann Diagn Pathol. 2015 Aug;19(4):198-202 PubMed
Pathol Int. 2009 May;59(5):322-5 PubMed
Mod Pathol. 2014 Feb;27(2):271-80 PubMed
Mod Pathol. 2006 Apr;19(4):494-503 PubMed
Adv Anat Pathol. 2014 Nov;21(6):394-410 PubMed
Nat Genet. 2014 May;46(5):424-6 PubMed
Am J Surg Pathol. 2011 Oct;35(10 ):e47-63 PubMed
Hum Pathol. 2006 Feb;37(2):168-72 PubMed
Eur Urol. 2015 Dec;68(6):970-7 PubMed
Hum Pathol. 2014 Nov;45(11):2247-54 PubMed
Int J Clin Exp Pathol. 2015 Aug 01;8(8):9638-42 PubMed
J Pathol. 2016 Feb;238(3):389-400 PubMed
Hum Pathol. 2014 Jul;45(7):1473-82 PubMed
Am J Surg Pathol. 2016 Apr;40(4):544-53 PubMed
PLoS One. 2013 May 01;8(5):e62483 PubMed
Cancer Res. 1999 Jan 1;59(1):74-9 PubMed
Pathology. 2015 Aug;47(5):439-45 PubMed
Am J Surg Pathol. 2015 Sep;39(9):1197-205 PubMed
Annu Rev Pathol. 2015;10:145-71 PubMed
Mod Pathol. 2016 Mar;29(3):302-14 PubMed
Histopathology. 1987 Oct;11(10):1083-92 PubMed
Int J Clin Exp Pathol. 2013;6(4):724-8 PubMed
Clin Cancer Res. 2014 Jan 1;20(1):21-7 PubMed
Nat Genet. 2011 Aug 07;43(9):875-8 PubMed
Eur Urol. 2016 Jul;70(1):106-119 PubMed
Pol J Pathol. 2014 Oct;65(3):237-40 PubMed
Mod Pathol. 2016 Jan;29(1):60-6 PubMed
Am J Med Genet C Semin Med Genet. 2014 Sep;166C(3):350-66 PubMed
